Vertex Pharmaceuticals Interest Expense:
0.00 for Dec. 31, 2012Vertex Pharmaceuticals Historical Interest Expense Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 0.00 |
| Dec. 31, 2012 | 3.793M |
| Sept. 30, 2012 | 4.56M |
| June 30, 2012 | 4.195M |
| March 31, 2012 | 4.105M |
| Dec. 31, 2011 | 12.43M |
| Sept. 30, 2011 | 7.059M |
| June 30, 2011 | 6.962M |
| March 31, 2011 | 12.00M |
| Dec. 31, 2010 | 7.686M |
| Sept. 30, 2010 | 3.951M |
| June 30, 2010 | 3.683M |
| March 31, 2010 | 3.955M |
| Dec. 31, 2009 | 4.562M |
| Sept. 30, 2009 | 1.927M |
| June 30, 2009 | 3.325M |
| March 31, 2009 | 3.378M |
| Dec. 31, 2008 | 0.00 |
| Sept. 30, 2008 | 0.00 |
| June 30, 2008 | 0.00 |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
A higher interest expense means that the company is paying more to its debtors. In general, a company's capital structure with a heavier debt focus will have higher interest expenses. Liquidity ratios such as EBIT/Interest Expense can help investors see if increasing Interest Expenses are problematic.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
VRTX Interest Expense Benchmarks
| Companies | |
|---|---|
| Gilead Sciences | 81.79M |
| Sarepta Therapeutics | 0.00 |
| Regeneron Pharmaceuticals | 11.68M |
VRTX Interest Expense Rankings
| Overall |
99th percentile 51 of 7590 |
| Sector |
98th percentile 9 of 651 in Healthcare |
| Industry |
97th percentile 5 of 238 in Biotechnology |
VRTX Interest Expense Range, Past 5 Years
| Minimum | 0.00 | Jun 2008 |
| Maximum | 12.43M | Dec 2011 |
| Average | 4.379M |
